RUBIN’S REFLECTIONS

Follow on Twitter @IBDMD

Message to Dr. Rubin’s Patients Related to COVID-19 Boosters

Aug 13, 2021

Dear Friends and Patients, I hope this message finds you well. Please excuse the group nature of this message, but I did want to reach out with the latest update about COVID-19, and vaccinations. If you want to skip right to the booster info, scroll down to #5 below....

Tweetorial to Provide Updates on COVID-19 for Patients with IBD

Jul 30, 2021

View Twitter Thread To watch me deliver the full lecture and view the presentation, click here. I recently gave a lecture about COVID-19 and vaccination with specific information for patients with IBD. This lecture was recorded on July 21st, before the CDC issued...

Tweetorial to Clarify the NYT Article From 15 April and Further Explain/Clarify the UK CLARITY IBD Study

Apr 18, 2021

Tweetorial to Clarify the NYT Article From 15 April and Further Explain/Clarify the UK CLARITY IBD Study David T. Rubin View Twitter Thread I've previously commented about the CLARITY IBD Study (Kennedy, et al). paper in this forum, but it bears repeating and further...

SARS Vaccine and IBD Tweetorial Summary from December 1

Dec 5, 2020

SARS Vaccine and IBD Tweetorial Summary from December 1 David T. Rubin View Twitter Thread Here are my thoughts and a few updates about SARS-CoV-2 vaccines, and also about important implications for our IBD patients. Development of multiple SARS-CoV-2 vaccines in the...

Approach to Management and Interpretation of Testing Results in Patients with IBD, with Particular Attention to Restarting Therapy

Apr 21, 2020

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine As testing for SARS-CoV-2 is expanded and serologic antibody testing becomes available, we are faced with a number of different clinical scenarios. I have outlined the different situations...

Three waves of Illness from the COVID-19 Pandemic

Apr 1, 2020

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine I've been thinking about what comes next, and how can we get ahead of this, and propose the following for consideration. I believe that there will be three waves of illness from the...

Long-Duration Vancomycin Linked to Lower Rates of C. diff Recurrence in IBD

by dtrubin | December 6, 2019 | In the Press | 0 Comments

Pritzker medical student Donald Lei's manuscript was accepted to the American Journal of Gastroenterology. Reuters Health Information reported on the study with comments by Dr. Rubin. "Our study did in fact demonstrate significantly reduced rates of recurrence...

IBD As We Age: Thoughts on Treatment and Management For Age 40 and Beyond

by dtrubin | December 4, 2019 | QoL, Rubin's Reflections | 0 Comments

There is a growing number of people diagnosed with IBD who are defined as “elderly”. This varies in definition but can be considered those who have IBD older than 50 or older than 60 or 65. I prefer the World Health Organization definition of >65. The two different...

Pursuing a Gut Feeling: Exploring Immune Cell Trafficking Inhibitors to Treat IBD

by David Rubin | March 2, 2021 | In the Press | 0 Comments

Click here to watch Dr. Rubin and Dr. Long review the role of cell trafficking in IBD pathogenesis and how therapies that modulate immune cell trafficking compare with other agents that target the inflammatory response in IBD.

Trial by Data: Chronic Disease & Data

by dtrubin | May 15, 2018 | Data, In the Press, monitoring | 0 Comments

Listen to Dr. Rubin featured on a podcast by Litmus Health, Trial by Data, exploring data-driven technologies and strategies shaping the future of clinical trials. Dr. Rubin talks about the importance of optimism in patient care and his own clinical trial using...

SARS Vaccine and IBD Tweetorial Summary from December 1

by David Rubin | December 5, 2020 | Coronavirus, Rubin's Reflections | 0 Comments

Dr. Rubin Taps in on “IBD Community Throwing Elbows Over Value of TDM” in Gastroenterology and Endoscopy News

by dtrubin | August 14, 2019 | In the Press, monitoring, therapies | 0 Comments

Dr. Mark Silverberg, Dr. David T Rubin, Dr. Laura Targownik, and Dr. Charabaty excitingly discuss why IBD specialists are divided on the topic of therapeutic drug monitoring (TDM). “If the drug is going to work but isn’t present in the body, it doesn’t do its job,”...

Dr. David T. Rubin Guest-Hosts IBD Drive Time

by David Rubin | June 7, 2023 | In the Press | 0 Comments

Take a listen to Dr. Rubin discuss the impact of inflammatory bowel disease on sexual function with University of Chicago's GI psychologist, Dr. Alyse Bedell, and pelvic floor physical therapist, Sarah Macaraeg.

How IBD Can Affect Patients’ Career and School Choices

by dtrubin | December 3, 2019 | QoL, Rubin's Reflections | 0 Comments

IBD, perhaps more than other chronic illnesses, can have a definite impact on a patient’s career choices and school performance. Therefore, I have definitely seen patients make decisions that are affected by their IBD. However, more often, I’ve seen patients overcome...

IBD Drive Time Podcast: Ethical Issues in Clinical Trials

by David Rubin | October 19, 2023 | In the Press | 0 Comments

Take a listen to the third episode of a four-part series wherein Professor Rubin guest-hosts the Gastroenterology Learning Network's IBD Drive Time and discusses the ethics of clinical trials in IBD, as well as challenges to recruitment, alongside Professor Severine...

IBD Drive Time: Dr. David Rubin, MD, on Ozanimod in Ulcerative Colitis

by David Rubin | August 6, 2021 | In the Press | 0 Comments

Click here to listen to Dr. Rubin speak with colleagues and IBD Drive Time hosts Raymond Cross, MD and Millie Long, MD on using newly-approved ozanimod in treating ulcerative colitis.